AU772947B2 - Triazolo-pyridazine derivatives as ligands for GABA receptors - Google Patents

Triazolo-pyridazine derivatives as ligands for GABA receptors Download PDF

Info

Publication number
AU772947B2
AU772947B2 AU30669/00A AU3066900A AU772947B2 AU 772947 B2 AU772947 B2 AU 772947B2 AU 30669/00 A AU30669/00 A AU 30669/00A AU 3066900 A AU3066900 A AU 3066900A AU 772947 B2 AU772947 B2 AU 772947B2
Authority
AU
Australia
Prior art keywords
compound
formula
pharmaceutically acceptable
triazolo
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU30669/00A
Other languages
English (en)
Other versions
AU3066900A (en
Inventor
William Robert Carling
Jose Luis Castro Pineiro
Richard Thomas Lewis
Kevin William Moore
Leslie Joseph Street
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9901744.4A external-priority patent/GB9901744D0/en
Priority claimed from GBGB9901743.6A external-priority patent/GB9901743D0/en
Priority claimed from GBGB9912429.9A external-priority patent/GB9912429D0/en
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Publication of AU3066900A publication Critical patent/AU3066900A/en
Application granted granted Critical
Publication of AU772947B2 publication Critical patent/AU772947B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU30669/00A 1999-01-27 2000-01-19 Triazolo-pyridazine derivatives as ligands for GABA receptors Ceased AU772947B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9901744.4A GB9901744D0 (en) 1999-01-27 1999-01-27 Therapeutic agents
GB9901743 1999-01-27
GB9901744 1999-01-27
GBGB9901743.6A GB9901743D0 (en) 1999-01-27 1999-01-27 Therapeutic agents
GB9912429 1999-05-27
GBGB9912429.9A GB9912429D0 (en) 1999-05-27 1999-05-27 Therapeutic agents
PCT/GB2000/000183 WO2000044752A1 (en) 1999-01-27 2000-01-19 Triazolo-pyridazine derivatives as ligands for gaba receptors

Publications (2)

Publication Number Publication Date
AU3066900A AU3066900A (en) 2000-08-18
AU772947B2 true AU772947B2 (en) 2004-05-13

Family

ID=27269629

Family Applications (1)

Application Number Title Priority Date Filing Date
AU30669/00A Ceased AU772947B2 (en) 1999-01-27 2000-01-19 Triazolo-pyridazine derivatives as ligands for GABA receptors

Country Status (9)

Country Link
US (2) US6500828B1 (cg-RX-API-DMAC7.html)
EP (1) EP1149102B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002535407A (cg-RX-API-DMAC7.html)
AT (1) ATE284403T1 (cg-RX-API-DMAC7.html)
AU (1) AU772947B2 (cg-RX-API-DMAC7.html)
CA (1) CA2359008C (cg-RX-API-DMAC7.html)
DE (1) DE60016566T2 (cg-RX-API-DMAC7.html)
ES (1) ES2232416T3 (cg-RX-API-DMAC7.html)
WO (1) WO2000044752A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000564D0 (en) 2000-01-11 2000-03-01 Merck Sharp & Dohme Therapeutic agents
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
US6960584B2 (en) 2001-04-10 2005-11-01 Merck & Co., Inc. Inhibitors of Akt activity
WO2002083140A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
DE60315876T2 (de) * 2002-11-28 2008-05-21 Neurosearch A/S Verfahren zum screening für verbindungen mit sedativer oder anxiolytischer potenz
WO2006061428A2 (en) * 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
HRP20140195T1 (hr) * 2008-08-29 2014-04-11 Concert Pharmaceuticals Inc. Supstituirani derivati triazolopiridazina
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2454259A1 (en) 2009-06-23 2012-05-23 Concert Pharmaceuticals Inc. Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
US20150099753A1 (en) * 2012-05-11 2015-04-09 Concert Pharmaceuticals Inc. Form 5 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
JP2015516440A (ja) * 2012-05-11 2015-06-11 コンサート ファーマシューティカルズ インコーポレイテッド 7−(tert−ブチル−d9)−3−(2,5−ジフルオロフェニル)−6−((1−メチル−1H−1,2,4−トリアゾール−5−イル)メトキシ)−[1,2,4]トリアゾロ[4,3−b]ピリダジンの2型多形
WO2013170241A1 (en) * 2012-05-11 2013-11-14 Concert Pharmaceuticals, Inc. Polymorphs of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolol[4,3b]pyridazine
WO2015095549A1 (en) * 2013-12-18 2015-06-25 Concert Pharmaceuticals, Inc. Dosage regimen for gabaa receptor subtype selective drug
HUE060943T2 (hu) * 2018-09-13 2023-04-28 Saniona As A gaba A receptor ligandum
AU2023258030A1 (en) * 2022-04-20 2024-10-17 Engrail Therapeutics, Inc. Gabaa receptor modulator salts, particles, and uses thereof
CN115837022B (zh) * 2023-02-20 2023-04-25 中山大学附属第八医院(深圳福田) 1,2,4三唑并4,3-b哒嗪衍生物在制备抗衰老药物中的应用
AU2024411621A1 (en) 2023-12-27 2026-06-18 Saniona A/S A gabaa receptor ligand and the use thereof in medicine, in particular in the treatment of epilepsy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004559A2 (en) * 1996-07-25 1998-02-05 Merck Sharp & Dohme Limited Substituted triazolo-pyridazine derivatives as ligands for gaba receptors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004559A2 (en) * 1996-07-25 1998-02-05 Merck Sharp & Dohme Limited Substituted triazolo-pyridazine derivatives as ligands for gaba receptors

Also Published As

Publication number Publication date
CA2359008A1 (en) 2000-08-03
CA2359008C (en) 2008-05-20
ES2232416T3 (es) 2005-06-01
US20030158203A1 (en) 2003-08-21
DE60016566T2 (de) 2005-12-15
WO2000044752A1 (en) 2000-08-03
JP2002535407A (ja) 2002-10-22
ATE284403T1 (de) 2004-12-15
EP1149102A1 (en) 2001-10-31
DE60016566D1 (de) 2005-01-13
AU3066900A (en) 2000-08-18
US6500828B1 (en) 2002-12-31
EP1149102B1 (en) 2004-12-08

Similar Documents

Publication Publication Date Title
CA2359008C (en) Triazolo-pyridazine derivatives as ligands for gaba receptors
AU757315B2 (en) A substituted triazolo-pyridazine derivative, pharmaceutical compositions made therefrom
AU2065799A (en) Triazolo-pyridazine derivatives as ligands for gaba receptors
US20030004180A1 (en) Pyrazolo-pyridine derivatives as ligands for gaba receptors
AU748013B2 (en) Triazolo-pyridazine derivatives as ligands for GABA receptors
AU2001244398B2 (en) Pyrazolo-triazine derivatives as ligands for gaba receptors
EP1212324B1 (en) Imidazo-triazine derivatives as ligands for gaba receptors
AU746866B2 (en) Triazolo-pyridazine derivatives as ligands for GABA receptors
US6291460B1 (en) Triazolo-pyridazine derivatives as ligands for GABA receptors
AU2306500A (en) Triazolo-pyridazine derivatives as ligands for gaba receptors
AU2002331942B2 (en) 7-tert-butyl-3-(2-fluorophenyl)-6-(2H-(1,2,4)triazol-3-ylmethoxy)-(1,2,4)triazolo (4,3-b) pyridazine for the treatment of anxiety and convulsions
AU2002331942A1 (en) 7-tert-butyl-3-(2-fluorophenyl)-6-(2H-(1,2,4)triazol-3-ylmethoxy)-(1,2,4)triazolo (4,3-b) pyridazine for the treatment of anxiety and convulsions
MXPA01000075A (en) A substituted triazolo-pyridazine derivative, pharmaceutical compositions made therefrom

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)